<DOC>
	<DOCNO>NCT02440763</DOCNO>
	<brief_summary>The key goal EUROSCA-NHS determine compare rate disease progression SCA1 , SCA2 , SCA3 SCA6 include determination order occurrence non-ataxia symptom , assessment activity daily live ( ADL ) quality life ( QoL ) , identification predictor disease progression survival .</brief_summary>
	<brief_title>The EUROSCA Natural History Study</brief_title>
	<detailed_description>The key goal EUROSCA-NHS determine compare rate disease progression SCA1 , SCA2 , SCA3 SCA6 . To end , newly develop validate ataxia scale ( Scale Assessment Rating Ataxia , SARA ) use . EUROSCA-NHS number secondary aim include determination order occurrence non-ataxia symptom , assessment activity daily live ( ADL ) quality life ( QoL ) , identification predictor disease progression survival . Substudies deal development brain atrophy , assess magnetic resonance imaging ( MRI ) , progression peripheral neuropathy , assess nerve conduction study , specific clinical aspect SCA .</detailed_description>
	<mesh_term>Spinocerebellar Ataxias</mesh_term>
	<mesh_term>Spinocerebellar Degenerations</mesh_term>
	<criteria>Inclusion criterion : Progressive , otherwise unexplained ataxia Positive genetic testing SCA1 , SCA2 , SCA3 , SCA6 Written inform consent patient legal agent Exclusion criterion :</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Natural History</keyword>
</DOC>